Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | BRD4 | O60885 | 1/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | GRM5 | P41594 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.44 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.44 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.44 |
| ▸ | KDM1A | O60341 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | CCR1 | P32246 | 1/20 | 0.43 |
| ▸ | CCR8 | P51685 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19630564 | 0.85 | SMN1; SMN2 (0.44) | SMN1; SMN2BRD4KCNH2GRM5ALDH1A1 | |
| SCHEMBL22061933 | 0.85 | MPO (0.45) | SMN1; SMN2BRD4GRM5ALDH1A1KDM4E | |
| SCHEMBL11330543 | 0.84 | KCNH2 (0.62) | SMN1; SMN2BRD4KCNH2ALDH1A1CALM1 | |
| SCHEMBL14082023 | 0.84 | CCR1 (0.52) | SMN1; SMN2KCNH2GRM5ALDH1A1KDM4E | |
| SCHEMBL19880302 | 0.84 | GRM5 (0.43) | SMN1; SMN2BRD4GRM5KEAP1NFE2L2 | |
| SCHEMBL19366496 | 0.82 | KEAP1 (0.44) | SMN1; SMN2BRD4ALDH1A1KDM4EKEAP1 | |
| SCHEMBL20313307 | 0.82 | TAAR1 (0.44) | SMN1; SMN2MEN1KMT2AMPO | |
| SCHEMBL5685326 | 0.82 | ESR1 (0.46) | SMN1; SMN2BRD4ALDH1A1KDM4EKEAP1 | |
| SCHEMBL1563917 | 0.82 | KCNH2 (0.73) | SMN1; SMN2KCNH2GRM5ALDH1A1KDM4E | |
| SCHEMBL30173447 | 0.82 | KCNH2 (0.73) | SMN1; SMN2KCNH2GRM5ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021126118-A1 | SYNTHESIS OF 2-(SUBSTITUTEDPHENYL)-5-(SUBSTITUTEDHETEROARYL)- 1H-BENZIMIDAZOLE DERIVATIVES AND INVESTIGATION OF THEIR BIOLOGICAL EFFECTS | ANADOLU ÜNİVERSİTESİ (TR) | 2021-06-24 | — | — | WO | disclosed |
| US-10818851-B2 | Condensed cyclic compound and organic light-emitting device including the same | SAMSUNG DISPLAY CO., LTD. (KR) | 2020-10-27 | — | — | US | disclosed |
| US-9899611-B2 | Condensed cyclic compound and organic light-emitting device including the same | SAMSUNG DISPLAY CO., LTD. (KR) | 2018-02-20 | — | — | US | disclosed |
| US-9879152-B2 | Block copolymers for directed self-assembly applications | INTERNATIONAL BUSINESS MACHINES CORPORATION (US) | 2018-01-30 | — | — | US | disclosed |
| US-9818960-B2 | Condensed cyclic compound and organic light-emitting device including the same | SAMSUNG DISPLAY CO., LTD. (KR) | 2017-11-14 | — | — | US | disclosed |
| US-9780313-B2 | Carbazole-based compound and organic light-emitting device including the same | SASMSUNG DISPLAY CO., LTD. (KR) | 2017-10-03 | — | — | US | disclosed |
| US-20170114246-A1 | BLOCK COPOLYMERS FOR DIRECTED SELF-ASSEMBLY APPLICATIONS | ELPIS TECHNOLOGIES INC. (CA) | 2017-04-27 | — | — | US | disclosed |
| US-9574107-B2 | Fluoro-alcohol additives for orientation control of block copolymers | INTERNATIONAL BUSINESS MACHINES CORPORATION (US) | 2017-02-21 | — | — | US | disclosed |
| US-20170033297-A1 | CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | SAMSUNG DISPLAY CO., LTD. (KR) | 2017-02-02 | — | — | US | disclosed |
| CN-101863826-B | Method for preparing 2-benzyl pyridine compound | USTC UNIV SCIENCE TECH CN | 2012-11-21 | — | — | CN | disclosed |
| EP-1219607-B1 | INTEGRASE INHIBITORS CONTAINING AROMATIC HETEROCYCLE DERIVATIVES | SHIONOGI & CO (JP) | 2011-04-06 | — | — | EP | disclosed |
| US-20110012100-A1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2011-01-20 | — | — | US | disclosed |
| CN-101863826-A | Method for preparing 2-benzyl pyridine compound | USTC UNIV SCIENCE TECH CN | 2010-10-20 | — | — | CN | disclosed |
| US-7582658-B2 | Bicyclic compound | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-09-01 | — | — | US | disclosed |
| US-7582658-B2 | Bicyclic compound | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-09-01 | — | — | US | disclosed |
| US-7576198-B1 | Integrase inhibitors containing aromatic heterocycle derivatives | SHIONOGI & CO., LTD. (JP) | 2009-08-18 | — | — | US | disclosed |
| EP-1219607-A1 | INTEGRASE INHIBITORS CONTAINING AROMATIC HETEROCYCLE DERIVATIVES | SHIONOGI & CO., LTD. (JP) | 2002-07-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170033297-A1 | CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | CCNE2, CCNE1, CCNA1 | SMN1; SMN2 470/4885BRD4 951/4885KCNH2 1238/4885 |
| US-10818851-B2 | Condensed cyclic compound and organic light-emitting device including the same | CCNE2, CCNE1, CCNA1 | SMN1; SMN2 470/4885BRD4 951/4885KCNH2 1238/4885 |
| US-20110012100-A1 | METAL COMPLEXES | AP1M1, AP3M1, SOD1 | SMN1; SMN2 3529/4885BRD4 2197/4885KCNH2 360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.